Browne L Daniel

CIK 00015975831 companyNEWARK, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001597583

Recent Transactions

50 trades

Other
Revance Therapeutics, Inc.
Common Stock
2019-06-28$11.02/sh+1,000→ 152,193 total
Sale
Revance Therapeutics, Inc.
Common Stock
2019-03-18$15.51/sh−11,613→ 151,193 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2019-03-15$15.45/sh−2,881→ 162,806 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2019-03-15$15.45/sh−3,256→ 165,687 total
Sale
Revance Therapeutics, Inc.
Common Stock
2019-02-19$17.68/sh−5,446→ 168,943 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2019-02-15$17.69/sh−3,154→ 174,389 total
Award
Revance Therapeutics, Inc.
Common Stock
2019-01-24+35,000→ 177,543 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2019-01-24+200,000→ 200,000 total
Other
Revance Therapeutics, Inc.
Common Stock
2018-06-29$23.33/sh+668→ 142,543 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2018-03-16+20,000→ 0 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2018-03-16$2.55/sh+20,000→ 147,327 total
Sale
Revance Therapeutics, Inc.
Common Stock
2018-03-16$31.43/sh−5,452→ 141,875 total
Sale
Revance Therapeutics, Inc.
Common Stock
2018-03-15$32.80/sh−1,000→ 130,208 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2018-03-15$31.65/sh−2,881→ 127,327 total
Sale
Revance Therapeutics, Inc.
Common Stock
2018-03-07$31.43/sh−27,283→ 131,208 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2018-02-15$31.75/sh−3,074→ 158,491 total
Award
Revance Therapeutics, Inc.
Common Stock
2018-02-08+28,250→ 161,565 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2018-02-08+169,000→ 169,000 total
Other
Revance Therapeutics, Inc.
Common Stock
2017-12-29$22.99/sh+127→ 133,315 total
Sale
Revance Therapeutics, Inc.
Common Stock
2017-11-22$24.94/sh−7,600→ 133,188 total
Sale
Revance Therapeutics, Inc.
Common Stock
2017-10-18$26.16/sh−7,662→ 140,788 total
Sale
Revance Therapeutics, Inc.
Common Stock
2017-09-20$23.58/sh−7,600→ 148,450 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2017-08-23$2.55/sh+331→ 178,850 total
Exercise/Conversion
Revance Therapeutics, Inc.
Stock Option (Right to Buy)
2017-08-23−331→ 10,990 total
Sale
Revance Therapeutics, Inc.
Common Stock
2017-08-23$22.76/sh−22,800→ 156,050 total
Other
Revance Therapeutics, Inc.
Common Stock
2017-06-30$18.32/sh+1,000→ 178,519 total
Exercise/Conversion
Revance Therapeutics, Inc.
Stock Option (Right to Buy)
2017-06-12−8,300→ 11,321 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2017-06-12$2.55/sh+8,300→ 177,519 total
Exercise/Conversion
Revance Therapeutics, Inc.
Stock Option (Right to Buy)
2017-05-30−5,000→ 19,621 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2017-05-30$2.55/sh+5,000→ 169,219 total
Sale
Revance Therapeutics, Inc.
Common Stock
2017-05-24$20.35/sh−19,713→ 164,219 total
Sale
Revance Therapeutics, Inc.
Common Stock
2017-05-22$20.20/sh−12,287→ 183,932 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2017-03-16$19.20/sh−3,171→ 196,219 total
Sale
Revance Therapeutics, Inc.
Common Stock
2017-02-22$20.56/sh−9,768→ 200,659 total
Sale
Revance Therapeutics, Inc.
Common Stock
2017-02-22$20.70/sh−1,269→ 199,390 total
Award
Revance Therapeutics, Inc.
Common Stock
2017-01-26+25,800→ 210,427 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2017-01-26+155,000→ 155,000 total
Sale
Revance Therapeutics, Inc.
Common Stock
2017-01-25$19.78/sh−12,000→ 184,627 total
Other
Revance Therapeutics, Inc.
Common Stock
2016-12-30$11.58/sh+1,000→ 196,627 total
Sale
Revance Therapeutics, Inc.
Common Stock
2016-12-28$20.94/sh−12,000→ 195,627 total
Sale
Revance Therapeutics, Inc.
Common Stock
2016-11-25$18.70/sh−822→ 207,627 total
Sale
Revance Therapeutics, Inc.
Common Stock
2016-11-25$17.86/sh−11,178→ 208,449 total
Sale
Revance Therapeutics, Inc.
Common Stock
2016-10-26$14.85/sh−12,000→ 219,627 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2016-05-19$17.11/sh−12,050→ 231,627 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2016-02-09+175,000→ 175,000 total
Award
Revance Therapeutics, Inc.
Common Stock
2016-02-09+25,000→ 243,677 total
Other
Revance Therapeutics, Inc.
Common Stock
2015-12-31$27.00/sh+262→ 218,677 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2015-12-30$2.55/sh+12,045→ 218,415 total
Exercise/Conversion
Revance Therapeutics, Inc.
Stock Option (right to buy)
2015-12-30−12,045→ 24,621 total
Other
Revance Therapeutics, Inc.
Common Stock
2015-06-30$14.16/sh+1,000→ 1,000 total

Companies

Revance Therapeutics, Inc.
Director, CEO and President

Recent Filings

Address

C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD

NEWARK, CA, 94560

View on SEC.gov